Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 02, 2022

Adding Chemotherapy to Endocrine Therapy After Surgery in Women Aged ≥70 Years With ER+/HER2− Breast Cancer and a High Genomic Grade Index

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial.
J. Clin. Oncol 2022 Jun 01;40(16_suppl)500, E Brain, AA Viansone, E Bourbouloux, et al

Further Reading